SION-719 is the first NBD1 stabilizer being evaluated in people living with cystic fibrosisTopline data expected in ...

600 mg once daily bexobrutideg oral dose cleared by global regulators for pivotal monotherapy trials in relapsed/refractory chronic lymphocytic ...

ThinkEquity will make its rule 10b-18 purchases (as defined in Rule 10b-18 of the Securities Exchange Act of 1934) in ...

Let's explore the zodiac sign of Aries with this fun fiery flow focusing on inner power. Join the 30-Day Yoga & Pilates ...

As Dallas City Hall’s future hangs in the balance with mounting maintenance issues, the site in the southern half of downtown ...

When Reserve Bank of India (RBI) directed banks to initiate insolvency proceedings against the country’s largest corporate ...

Plato, one of the greatest philosophers of ancient Greece, continues to influence how we think about truth, justice, love, ...

SION-719 is the first NBD1 stabilizer being evaluated in people living with cystic fibrosis Topline data expected in mid-2026 WALTHAM, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that a global licensing and collaboration agreement with Novartis, previously announced on September 2, 2025, has now closed. Closing of ...

Submitted a New Drug Application (NDA) for accelerated approval of bitopertin in erythropoietic protoporphyria (EPP) on September 29, 2025, and subsequently was awarded the FDA Commissioner's National ...

This valuable study addresses the effects of selection on aggression on fitness and life-history trade-offs in Drosophila melanogaster. However, the evidence presented is incomplete and does not ...

The crisis has evolved from isolated use to systematic household penetration, with women now increasingly entangled in supply ...